학술논문
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial of the European mantle cell lymphoma network
Document Type
Article
Author
Fischer, L.; Schmidt, C.; Silkenstedt, E.; Weigert, O.; Hiddemann, W.; Unterhalt, M.; Hoster, E.; Dreyling, M.; Jiang, L.; Dürig, J.; Stilgenbauer, S.; Bouabdallah, K.; Solal-Celigny, P.; Scholz, C.W.; Feugier, P.; de Wit, M.; Trappe, R.U.; Hallek, M.; Graeven, U.; Hänel, M.; Hoffmann, M.; Delwail, V.; Macro, M.; Greiner, J.; Giagounidis, A.A.N.; Dargel, B.; Durot, E.; Foussard, C.; Pott, C.; Klapper, W.; Ribrag, V.
Source
In: Leukemia . (Leukemia, June 2024, 38(6):1307-1314)
Subject
Language
English
ISSN
14765551
08876924
08876924